ArticleHepatology (Baltimore, Md.)2026

Repurposing Resmetirom suppresses MASH-associated hepatocellular carcinoma, with mechanistic implications of MDK/LRP1-mediated metabolic reprogramming and immunosuppression.

Vanilla Xin Zhang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.